In recent years, there has been a shift towards non-anthracycline-containing chemotherapy regimens in the treatment of HER2-positive BC to decrease long-term adverse outcomes, such as cardiotoxicity and leukemia [13]. The gene discussed is ERBB2; the disease is breast cancer.